# TR NEURO



- Automatic LVO and ICH detection with industry validated-sensitivity, specifcity and accuracy.

- Patented accept, reject and rerun capabilities keeps physicians in charge of what persists in the final patient record.

- Robust insight access and communication experience, from any mobile device, informs through to the point of care.

In neuro-vascular emergencies, delays in diagnosis and treatment can shorten or reduce the patient's quality of life and contribute to substantially higher healthcare and societal costs. Because of this, rapid imaging evaluation and precise assessment for surgical intervention are critical. However, reducing time-to-treatment requires resources that are not equally available across all organizations.

We created TR Neuro to level the playing field. By facilitating earlier disease diagnosis and more natural stroke-team communication, it can enhance your facility's emergency preparedness—enabling you to give the highest-quality treatment when it's needed most.

# TERARECON
A ConcertAI Company

www.terarecon.com

# Because Time is Brain

TeraRecon's TR Neuro is an AI-assisted specialty clinical workflow solution, purpose-built for hemorrhagic and ischemic neurological emergencies on CT and CTA imaging.

TR Neuro automatically generates LVO, ICH, and ASPECTS* algorithm results to give a complete picture of the patient and follow them through to the point of care. If applicable, autogenerated CT perfusion maps can also be viewed and used for quick clinical triage. All of these features work together to help neurologists, radiologists interventionalists, and the rest of your stroke team with their diagnostic and bedside needs.

*This offering is CE marked only.

## Performance Results

| ICH | | | LVO | | | ASPECTS | | |
|---|---|---|---|---|---|---|---|---|
| Accuracy | 96% | | Accuracy | 96% | | Accuracy | 86.6% | |
| Sensitivity | 91.4% | | Sensitivity | 97.9% | | Sensitivity | 86.6% | |
| Specificity | 97.5% | | Specificity | 97.6% | | Specificity | 77.1% | |

# A System of Trust – By Design

Today, AI adoption is hindered by concerns that it will interfere with physicians' judgment and preferences. TeraRecon addresses this by incorporating interactive, AI-enhanced insights directly into existing technologies, including desktop and mobile platforms.

The result of this work is a unique and clinically-enriched AI interoperability platform that delivers an exceptional, yet familiar experience that works alongside or within a physician's current system. Additionally, patented capabilities to accept or reject AI outputs permit map adjustment and re-running of AI algorithms.

## Care Team Insights On-The-Go

A powerful mobile app allows physicians to review, agree, or disagree with findings by using standard finger gestures for slice scrolling, phase scrolling, two-finger pan, pinch-zoom, swiping between images, and window/level adjustment.

For added convenience, HIPPA-compliant in-app communication—including instant messaging, group chat, and patient-level chat—improves care coordination and can reduce delays caused by manual or out-of-context communication workflows.



## Improving the Radiologist's Experience

Gain additional efficiencies with access to the HL7 data that can drive optimization and better prioritization of the radiologist's worklist.  Further, the same HL7 data can improve other clinical systems that accept this type of input.

And now, with TeraRecon Analytics, you can track various metrics such as user availability, platform resource utilization, AI result success rate reports, and algorithm frequency to gain insights and optimize the user experience.

# Improve Financial and Patient Outcomes

**Consider the following scenario:**



Consider the following scenario: A six-hospital health system, including two advanced primary stroke centers and one comprehensive stroke center, records 3000 stroke admissions annually, of which 6% receive surgical intervention. If the average rate of surgical intervention improved by just 1% through more timely assessment, the lives of 15 extra stroke sufferers would be improved, and the health system would benefit from an additional $840,000** in Medicare reimbursements alone. In addition, TeraRecon Neuro subscription-based packaging boasts therapeutic efficacy as well as reducing operational, start-up, procurement, and capital expenditures that hinder the achievement of optimum outcomes for patient

With TeraRecon Neuro, the experience IS the solution. More than 1200 health sites around the world trust TeraRecon's advanced visualization solutions for assessing neurological and neurovascular emergencies —while benefiting from a powerful clinical experience and a measurable ROI.

** Calculated as $28,000 per MT DRG (source Definitive Healthcare)

# TERARECON
A ConcertAI Company

## www.terarecon.com